{"doi":"10.1200/jco.23.02019","title":"Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors","abstract":"PURPOSE T cells modified with chimeric antigen receptors (CARTs) have demonstrated efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has been limited. To enhance T cell activity against GD2+ CNS malignancies, we modified GD2-directed CART cells (GD2.CARTs) with a constitutively active interleukin (IL)-7 receptor (C7R-GD2.CARTs). METHODS Patients age 1-21 years with H3K27-altered diffuse midline glioma (DMG) or other recurrent GD2-expressing CNS tumors were eligible for this phase I trial (ClinicalTrials.gov identifier: NCT04099797 ). All subjects received standard-of-care adjuvant radiation therapy or chemotherapy before study enrollment. The first treatment cohort received GD2.CARTs alone (1 × 10 7 cells/m 2 ), and subsequent cohorts received C7R-GD2.CARTs at two dose levels (1 × 10 7 cells/m 2 ; 3 × 10 7 cells/m 2 ). Standard lymphodepletion with cyclophosphamide and fludarabine was included at all dose levels. RESULTS Eleven patients (age 4-18 years) received therapy without dose-limiting toxicity. The GD2.CART cohort did not experience toxicity, but had disease progression after brief improvement of residual neurologic deficits (≤3 weeks). The C7R-GD2.CART cohort developed grade 1 tumor inflammation–associated neurotoxicity in seven of eight (88%) cases, controllable with anakinra. Cytokine release syndrome was observed in six of eight (75%, grade 1 in all but one patient) and associated with increased circulating IL-6 and IP-10 ( P < .05). Patients receiving C7R-GD2.CARTs experienced temporary improvement from baseline neurologic deficits (range, 2 to >12 months), and seven of eight (88%) remained eligible for additional treatment cycles (range 2-4 cycles). Partial responses by iRANO criteria were observed in two of seven (29%) patients with DMG treated by C7R-GD2.CARTs. CONCLUSION Intravenous GD2.CARTs with and without C7R were well tolerated. Patients treated with C7R-GD2.CARTs exhibited transient improvement of neurologic deficits and increased circulating cytokines/chemokines. Treatment with C7R-GD2.CARTs represents a novel approach warranting further investigation for children with these incurable CNS cancers.","journal":"Journal of Clinical Oncology","year":2024,"id":417259,"datarank":1.7990514373855269,"base_score":4.330733340286331,"endowment":4.330733340286331,"self_citation_contribution":0.6496100010429497,"citation_network_contribution":1.1494414363425771,"self_endowment_contribution":0.6496100010429497,"citer_contribution":1.1494414363425771,"corpus_percentile":null,"corpus_rank":null,"citation_count":75,"citer_count":71,"citers_with_citation_signal":48,"citers_with_endowment":48,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9576,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04099797"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":640318,"name":"Austin J. Stuckert","orcid":"0000-0002-5938-7495","position":1,"is_corresponding":false},{"id":876266,"name":"Candise Tat","orcid":"0000-0003-2611-3858","position":2,"is_corresponding":false},{"id":1202783,"name":"Mark D. White","orcid":"0000-0002-1431-0339","position":3,"is_corresponding":false},{"id":1202784,"name":"Lucia Ruggieri","orcid":"0000-0001-9820-3890","position":4,"is_corresponding":false},{"id":254044,"name":"Huimin Zhang","orcid":"0009-0001-1041-6400","position":5,"is_corresponding":false},{"id":256824,"name":"Birju Mehta","orcid":null,"position":6,"is_corresponding":false},{"id":928151,"name":"Natalia Lapteva","orcid":null,"position":7,"is_corresponding":false},{"id":978936,"name":"Zhuyong Mei","orcid":"0000-0002-8843-5767","position":8,"is_corresponding":false},{"id":272848,"name":"Angela M. Major","orcid":null,"position":9,"is_corresponding":false},{"id":1114281,"name":"Sachin G. Thakkar","orcid":"0000-0002-7077-4971","position":10,"is_corresponding":false},{"id":876831,"name":"Thomas Shum","orcid":null,"position":11,"is_corresponding":false},{"id":624298,"name":"Kathan Parikh","orcid":null,"position":12,"is_corresponding":false},{"id":466119,"name":"Meng-Fen Wu","orcid":"0000-0001-7690-109X","position":13,"is_corresponding":false},{"id":132350,"name":"Holly B. Lindsay","orcid":"0000-0001-5654-841X","position":14,"is_corresponding":false},{"id":876267,"name":"Lauren Scherer","orcid":"0000-0002-6326-1166","position":15,"is_corresponding":false},{"id":1202785,"name":"Meghan Shekar","orcid":"0000-0002-6711-9896","position":16,"is_corresponding":false},{"id":1203548,"name":"Darryl Kinnear","orcid":null,"position":17,"is_corresponding":false},{"id":743582,"name":"Melissa M. Blessing","orcid":"0000-0002-4014-4426","position":18,"is_corresponding":false},{"id":290377,"name":"Patricia Baxter","orcid":null,"position":19,"is_corresponding":false},{"id":368660,"name":"Tao Wang","orcid":"0000-0003-1957-7160","position":20,"is_corresponding":false},{"id":254046,"name":"Bambi Grilley","orcid":"0000-0003-4800-6439","position":21,"is_corresponding":false},{"id":1051206,"name":"Karen Moeller","orcid":null,"position":22,"is_corresponding":false},{"id":140436,"name":"John Hicks","orcid":null,"position":23,"is_corresponding":false},{"id":35767,"name":"Angshumoy Roy","orcid":"0000-0001-7248-8576","position":24,"is_corresponding":false},{"id":478864,"name":"Jamie N. Anastas","orcid":"0000-0002-5317-5352","position":25,"is_corresponding":false},{"id":1202786,"name":"Fatema Malbari","orcid":"0000-0002-4159-1359","position":26,"is_corresponding":false},{"id":1202787,"name":"Guillermo Aldave","orcid":"0000-0001-8286-5830","position":27,"is_corresponding":false},{"id":342733,"name":"Murali Chintagumpala","orcid":"0000-0003-2686-6737","position":28,"is_corresponding":false},{"id":288905,"name":"Susan M. Blaney","orcid":"0000-0002-6194-4799","position":29,"is_corresponding":false},{"id":2232,"name":"D. Williams Parsons","orcid":"0000-0002-8775-3501","position":30,"is_corresponding":false},{"id":3643,"name":"Malcolm K. Brenner","orcid":"0000-0002-3657-7675","position":31,"is_corresponding":false},{"id":254048,"name":"Helen E. Heslop","orcid":"0000-0001-7049-7698","position":32,"is_corresponding":false},{"id":282364,"name":"Cliona M. Rooney","orcid":"0000-0003-3210-2864","position":33,"is_corresponding":false},{"id":622688,"name":"Bilal Omer","orcid":"0000-0002-1479-5305","position":34,"is_corresponding":false},{"id":35766,"name":"Frank Y. Lin","orcid":"0000-0001-6738-844X","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T01:56:50.743370Z","pmid":"38771986","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}